Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors

被引：0
|
作者：
Peng, Yongde [1 ]
Zhang, Bin [2 ]
Hou, Jianing [2 ]
机构：
[1] Shanghai First Peoples Hosp, Shanghai, Peoples R China
[2] Lilly Suzhou Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2019年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1524615
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors
    Jianhua Ma
    Bin Zhang
    Jianing Hou
    Yongde Peng
    Diabetes Therapy, 2021, 12 : 211 - 222
  • [2] Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors
    Ma, Jianhua
    Zhang, Bin
    Hou, Jianing
    Peng, Yongde
    DIABETES THERAPY, 2021, 12 (01) : 211 - 222
  • [3] Factors associated with HbA1c reduction in Asian patients with T2DM: an analysis of the FINE Asia registry
    Kiat, K. Tan Eng
    Ji, L.
    Suastika, K.
    Wang, J.
    Wang, E.
    Lin, J.
    Tsai, S. -T.
    DIABETOLOGIA, 2011, 54 : S428 - S428
  • [4] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Zhou, Yan
    Zhu, Jiankun
    Wu, Haiya
    Deng, Yuying
    Ji, Qiuhe
    DIABETES THERAPY, 2021, 12 (10) : 2677 - 2690
  • [5] Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors
    Yan Zhou
    Jiankun Zhu
    Haiya Wu
    Yuying Deng
    Qiuhe Ji
    Diabetes Therapy, 2021, 12 : 2677 - 2690
  • [6] Efficacy by Baseline BMI with Once Weekly Dulaglutide in Chinese T2DM Patients
    Shi, Yongquan
    Zhang, Bin
    Wu, Haiya
    DIABETES, 2019, 68
  • [7] Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
    Raffaella Gentilella
    Irene Romera
    Claudia Nicolay
    Raffaella Buzzetti
    Luis Alberto Vázquez
    Giorgio Sesti
    Diabetes Therapy, 2019, 10 : 1113 - 1125
  • [8] Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
    Gentilella, Raffaella
    Romera, Irene
    Nicolay, Claudia
    Buzzetti, Raffaella
    Alberto Vazquez, Luis
    Sesti, Giorgio
    DIABETES THERAPY, 2019, 10 (03) : 1113 - 1125
  • [9] EXENATIDE ONCE-WEEKLY (EQW) PHARMACOKINETICS AND HBA1C EXPOSURE RESPONSE ARE SIMILAR BETWEEN ADOLESCENT PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AND ADULTS WITH T2DM.
    Edlund, H.
    Melin, J.
    Penland, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S40 - S40
  • [10] Efficacy and Safety of Vildagliptin in Triple Combination With Metformin Plus Sulfonylurea in Subgroup of Patients With T2DM and Baseline HbA1c
    Lukashevich, Valentina
    Araga, Mako
    Kothny, Wolfgang
    DIABETES, 2013, 62 : A294 - A294
12345